Viewing nowCurasil Tablet 125 mg (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Yuhan Corporation

MFDS item code 200300413 · Approved 2003.09.09 · Insurance code 642102340
Treatment of dermatophytosis (tinea pedis, tinea corporis, etc.) and onychomycosis
This medication is used for the treatment of dermatophytosis caused by dermatophytes such as tinea pedis, tinea corporis, and tinea cruris in adults, as well as for the treatment of tinea capitis in children.
As terbinafine, administer 125 mg once, twice a day, or 250 mg once daily. The treatment duration varies by condition as follows: 1) Dermatophytosis Tinea pedis (interdigital type, plantar type/mocha type): 2–6 weeks Tinea corporis: 2–4 weeks Tinea cruris: 2–4 weeks 2) Onychomycosis Typically administered for 6 weeks to 3 months. If the infection is in the fingernail or a relatively small toe, or if the patient is younger, the treatment duration may be reduced to less than 3 months. The treatment duration for toenail infections is typically sufficient at 3 months, but in some patients, it may take 6 months or longer. If the patient has slow nail growth, the treatment duration may be prolonged. 2. Pediatric: Administer to children over 2 years of age. There is insufficient experience for administering to patients under 2 years, so it is not recommended. Tinea capitis: 4 weeks. Tinea capitis mainly occurs in children. To prevent recurrence of infection, treatment should be conducted for a regularly defined period. 1) Weight under 20 kg (under 5 years): administer 62.5 mg once daily. Due to a lack of experience, the decision to administer should consider the benefits and risks of treatment. 2) Weight 20–40 kg (5–12 years): administer 125 mg once daily. 3) Weight over 40 kg (over 12 years): administer 250 mg once daily. 3. Patients with renal impairment In patients with a creatinine clearance rate of less than 50 mL per minute, reduce the daily dose by half.
Administer to children over 2 years of age. Tinea capitis: 4 weeks 1) Weight under 20 kg (under 5 years): administer 62.5 mg once daily. 2) Weight 20–40 kg (5–12 years):
This medication should generally not be used in patients with chronic liver disease or active liver disease. Liver function tests must be performed before administration, and regular liver function tests should be conducted during treatment. If symptoms of liver dysfunction appear, stop taking this medication immediately and consult a physician. It is not recommended for patients with blood disorders, severe renal impairment, nursing women, or infants under 2 years of age. Use with caution in patients with decreased renal function, elderly patients, or underweight children. Discontinue use immediately if severe rash or allergic reactions occur. This medication may affect the liver and kidneys, so regular liver function and blood tests should be performed while on this medication. Dizziness or drowsiness may occur with this medication, so caution should be taken when driving or operating machinery. Interactions with other medications may occur, so be sure to inform your doctor or pharmacist about any other medications you are taking. Women who are pregnant or could become pregnant should consult a physician before taking this medication. Nursing women should discontinue breastfeeding while on this medication. Safety in children, particularly infants under 2 years of age, has not been established, and therefore it is not recommended. In the case of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may occur, and prompt medical attention should be sought. Store this medication out of the reach of children and keep it in a closed container away from direct sunlight at room temperature.
Liver failure, hepatitis, cholestasis, jaundice, symptoms of impaired liver function (persistent nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, soft stools), Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, rhabdomyolysis, hypotension, respiratory distress, chest tightness, anaphylactic reactions (including angioedema and systemic lupus erythematosus)
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C. Proper storage will help preserve the effectiveness of the medication.
White to off-white round tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Yuhan Corporation
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.